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1116 (71.8%) non-CCB users (249±84 vs. 229±84, p<0.001). Patients with CCBs
showed more unfavorable baseline characteristics such as old age, hypertension,
dyslipidemia, chronic kidney disease, higher body mass index. The genotyping of
CYP3A4 (IVS10+12G/A) was successful in 1259 patients, and its distribution was
61.3%, 32.9% and 3.9% for GG, GA and AA-genotypes, respectively. After adjustment
for possible confounding factors, the number of A allele was associated with increased
vulnerability to CCB use (Effect of CCB use PRU-difference: +11 PRU, p=0.088, +19
PRU, p=0.038, +42 PRU, p=0.051, for patients with 0, 1, and 2 A alleles, respectively,
+20 PRU, p=0.020 for GA/AA genotypes). Using a defined cutoff value for high OPR,
only in the GA/AA genotypes did CCB use result in significantly increased risk for
high OPR (OR 1.70, 95% CI 1.09-2.64, p=0.018).
Conclusion: CCB use is associated with increased OPR. The number of CYP3A4
(IVS10+12G/A) A-allele may be associated with an increased vulnerability to the
effects of CCBs on clopidogrel response variation.
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Background: The optimal duration of clopidogrel, particularly following DES,
remains contentious. Previous studies have observed a clustering of adverse events, in
particular stent thrombosis (ST), 1 year after clopidogrel cessation in DES. It has been
suggested that this may be due to a pro-thrombotic and/or pro-inflammatory response.
We investigated the effect of clopidogrel cessation on platelet reactivity and markers
of vascular inflammation in DES patients.
Methods: 33 patients on dual antiplatelet therapy and due to stop clopidogrel at 1 year
following DES were investigated. Venesection was performed at 4wks and 24hrs before
and 24hrs, 48hrs, 1, 2 and 4wks after clopidogrel cessation. At each time-point: (i)
ADP- and AA-induced platelet reactivity were measured using a simple, rapid, near-
patient platelet function test known as short Thrombelastography (s-TEG) that has
been developed and validated by this group; (ii) inflammatory biomarkers IL-6,
sCD40L and hSCRP were measured, and (iii) serum thromboxane B2 (TXB2) levels
were measured to assess the efficacy of aspirin.
Results: Following clopidogrel withdrawal, there was (i) a predictable increase in
ADP- and an unexpected and significant rise in AA-induced platelet aggregation (ii) a
significant decline in IL-6 and hsCRP at 1wk (p=0.006) and 4wks (p=0.003)
respectively. TXB2 was consistently suppressed confirming inhibition of COX-1 by
aspirin.
Increase in ADP- and AA-induced platelet aggregation following clopidogrel
cessation measured using s-TEG (AUC15 – area under the curve at 15 minutes;
Error bars represent mean+/-95%CI)
Conclusion: We have described for the first time an aspirin-independent time-
dependent increase in AA-induced clotting following clopidogrel cessation in DES.
As well as potentially helping to explain the clustering of ST events observed early
after withdrawal of long term clopidogrel, these findings raise important questions:(i)
should clopidogrel be tapered rather than abruptly withdrawn at 1 year? (ii) should we
discontinue aspirin instead of clopidogrel at 1 year? and (iii) is AA-induced clotting
an appropriate test of aspirin sensitivity? These findings demand further investigation.
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Background: Activities of genetically regulated cytochrome enzymes, drug
transporters, and paraoxonase have been postulated to be associated with clopidogrel
response variability. However, controversy exists regarding which genetic variations
influence the antiplatelet effect of clopidogrel.
Methods: Clopidogrel on-treatment platelet reactivity (OPR) was measured and
genotyping of CYP1A2*1F, CYP2B6*6, CYP2C19*2, CYP2C19*3, CYP2C19*17,
CYP3A4 (IVS10+12G/A), CYP3A5*3, ABCB1 C3435T, and PON-1 Q192R was
performed in 1555 consecutive patients who underwent percutaneous coronary
intervention at Seoul National University Hospital.
Results: The mean OPR of the entire population was 235±84 (P2Y12 Reaction Units,
PRU). Genotyping results were available in 1299 patients. As for CYP2C19, 528
patients (40.8%) had no loss-of-function (LOF) allele, 629 patients (40.8%) 1 LOF-
allele and 137 patients (8.7%) 2 LOF-alleles. After adjustment for possible
confounders, each LOF-allele was associated with an OPR increase of 25 PRU (+25
PRU for 1 LOF, p=0.001, +52 PRU for 2 LOF-alleles, p<0.001). Genetic variations of
CYP1A2, 2B6, 3A4, and 3A5, as well as ABCB1 and PON-1 genes were not associated
with clopidogrel response variability. Using a defined cut-off value for high OPR, only
the CYP2C19 genotype was an independent predictor of high-OPR (OR 1.93, 95% CI
1.60-2.33, p<0.001). In subgroup analysis, among patients with 2 LOF-alleles of
CYP2C19, there was a further increase of OPR in the CYP3A4 (IVS10+12G/A)
GA/AA versus GG genotypes (288±10 PRU vs. 256±8.4 PRU, p=0.019).
Conclusion: Among genes postulated to be involved in clopidogrel metabolism, only
the CYP2C19 genotype is associated with response variability. PON-1 and ABCB1
genetic variants did not affect clopidogrel OPR.
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Background: Numerous studies have shown the benefits of dual antiplatelet therapy
(DAT) in patients undergoing percutaneous coronary interventions (PCI) with drug
eluting stent (DES) implantation. The main benefit is a decrease in stent thrombosis
(ST) incidence, and, hence, in myocardial infarctions (MIs) and deaths. Nevertheless,
prolonged DAT is related to a greater incidence of bleeding complications. The optimal
length of DAT is yet to be determined. The study aims to assess long-term safety of
DAT in patients with coronary artery disease treated with DES.
Methods: The study group consisted of 500 patients with at least one DES.152 patients
received zotarolimus eluting stents, while 348 everolimus eluting stents. The mean
time of observation was 15.8 months (474 days). All patients received ASA 75mg in
combination with clopidogrel 75mg for at least 12 months. The patients were followed
up during hospitalization, and then after 1, 6, 12, 24, 36 months following the index
procedure. The primary endpoint concerned the rate of any bleeding complications,
defined according to the modified Global Use of Strategies to Open Occluded Coronary
Arteries (GUSTO) scale as severe/life threatening or as moderate bleedings without
hemodynamic compromise within the first 12 months after the index procedure.
Results: The population under study presented numerous risk factors of cardiovascular
disease.The patients’ mean age was 63.0±9.6 years, 362 patients were males (72.4%),
269 (53.8%) had a history of MI, 377 (75.4%) were hypertensive, 142 (28.4%) were
diabetic, 50 (10.0%) had peripheral artery disease and 24 (4.8%) had renal failure.
During long-term observation, bleeding complications occurred in only 14 patients
(2.8%). In 4 cases (0.8%), severe/life threatening bleeding was observed, and in another
10 cases (2.0%) a moderate bleeding occurred. Most bleedings - 12 (2.4%) - occurred
within the first 12 months of observation.
Conclusion: Severe/moderate bleeding is not a very common complication in patients
on prolonged DAT. An analysis of multiple risk factors of this complication will be
supplemented later.
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Background: Not all patients have the same response to the inhibitory effect of platelet
aggregation mediated by aspirin (ASA). Patients with diabetes mellitus are
characterized by enhanced platelet reactivity and a reduced response to oral antiplatelet
medications. Objectives:1) To determine the prevalence of hyporesponsiveness (HR)
to ASA in type 2 diabetic patients (DM) treated with percutaneous coronary
intervention (PCI) using drug-eluting stent and dual antiplatelet therapy using two
methods of measurement of antiplatelet,VerifyNow® Aspirin Assay (Accumetrics )
(VN) and platelet function analyser PFA-100® (Dade-Behring) (PFA). 2) To analyse
the correlation of the results obtained by both methods.
Methods: Patients DM were included with non−ST-segment elevation acute coronary
syndrome who underwent PCI and Xience V stent. After PCI the in vitro response to
antiplatelet therapy measured by ASA was determined, using the platelet function tests
VN and by the (PFA). The degree of correlation between both methods was determined
by calculating the Spearman correlation coefficient (rs) and the concordance with the
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